The chromatin remodeling component Arid1a is a suppressor of spontaneous mammary tumors in mice

Genetics

Volumn 203, Issue 4, 2016, Pages 1601-1611

  Kartha, Nithya ^a   Shen, Lishuang ^a,b   Maskin, Carolyn ^a   Wallace, Marsha ^a,c   Schimenti, John C ^a  

^a Department of Obstetrics Gynecology   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arid1a; Breast cancer; Cell cycle; Mouse; Senescence; Tumor suppressor

Indexed keywords

ARID1A PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ONCOPROTEIN; TRANSCRIPTOME; TRP53 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, MOUSE; ARID1B PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CHROMATIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER GROWTH; CANCER MODEL; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR CELL; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; BIOSYNTHESIS; CHROMATIN; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MUTATION; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MUTATION; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84981541485     PISSN: 00166731     EISSN: 19432631     Source Type: Journal    
DOI: 10.1534/genetics.115.184879     Document Type: Article

References (53)

1. American Cancer Society, 2014 Breast Cancer Facts and Figures 2015–2016. Available at cancer.org. Accessed June 21, 2016.
2. Andreasen, P. A., L. Kjoller, L. Christensen, and M. J. Duffy, 1997 The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72: 1–22.
3. Bai, G., M. B. Smolka, and J. C. Schimenti, 2016 Chronic DNA replication stress reduces replicative lifespan of cells by TRP53-dependent, microRNA-assisted MCM2–7 downregulation. PLoS Genet. 12: e1005787.
4. Bitler, B. G., N. Fatkhutdinov, and R. Zhang, 2015 Potential therapeutic targets in ARID1A-mutated cancers. Expert Opin. Ther. Targets 19: 1419–1422.
5. Bosse, T., N. T. ter Haar, L. M. Seeber, P. J. v Diest, F. J. Hes et al., 2013 Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod. Pathol. 26: 1525–1535.
6. Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou et al., 1998 Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501.
7. Butt, A. J., K. A. Dickson, F. McDougall, and R. C. Baxter, 2003 Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J. Biol. Chem. 278: 29676–29685.
8. Cajuso, T., U. A. Hanninen, J. Kondelin, A. E. Gylfe, T. Tanskanen et al., 2014 Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int. J. Cancer 135: 611–623.
9. Chandler, R. L., J. Brennan, J. C. Schisler, D. Serber, C. Patterson et al., 2013 ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF. Mol. Cell. Biol. 33: 265–280.
10. Chandler, R. L., J. S. Damrauer, J. R. Raab, J. C. Schisler, M. D. Wilkerson et al., 2015 Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat. Commun. 6: 6118.
11. Chavez, A., J. Scheiman, S. Vora, B. W. Pruitt, M. Tuttle et al., 2015 Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12: 326–328.
12. Cheng, L., Z. Zhou, A. Flesken-Nikitin, I. A. Toshkov, W. Wang et al., 2010 Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. Oncogene 29: 5700–5711.
13. Cho, H. D., J. E. Lee, H. Y. Jung, M. H. Oh, J. H. Lee et al., 2015 Loss of tumor suppressor ARID1A protein expression correlates with poor prognosis in patients with primary breast cancer. J. Breast Cancer 18: 339–346.
14. Chuang, C. H., D. Yang, G. Bai, A. Freeland, S. C. Pruitt et al., 2012 Post-transcriptional homeostasis and regulation of MCM2–7 in mammalian cells. Nucleic Acids Res. 40: 4914–4924.
15. Ciriello, G., M. L. Gatza, A. H. Beck, M. D. Wilkerson, S. K. Rhie et al., 2015 Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163: 506–519.
16. Cornen, S., J. Adelaide, F. Bertucci, P. Finetti, A. Guille et al., 2012 Mutations and deletions of ARID1A in breast tumors. Oncogene 31: 4255–4256.
17. Eirew, P., A. Steif, J. Khattra, G. Ha, D. Yap et al., 2015 Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518: 422–426.
18. Gao, X., P. Tate, P. Hu, R. Tjian, W. C. Skarnes et al., 2008 ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc. Natl. Acad. Sci. USA 105: 6656–6661.
19. Gilbert, L. A., M. A. Horlbeck, B. Adamson, J. E. Villalta, Y. Chen et al., 2014 Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159: 647–661.
20. Guan, B., T. L. Wang, and M. Shih Ie, 2011 ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 71: 6718–6727.
21. Guan, B., Y. S. Rahmanto, R. C. Wu, Y. Wang, Z. Wang et al., 2014 Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J. Natl. Cancer Inst. Avalable at: http://jnci.oxfordjournals.org/content/106/7/dju146.full.
22. Imielinski, M., A. H. Berger, P. S. Hammerman, B. Hernandez, T. J. Pugh et al., 2012 Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107–1120.
23. Inoue, H., S. Giannakopoulos, C. N. Parkhurst, T. Matsumura, E. A. Kono et al., 2011 Target genes of the largest human SWI/SNF complex subunit control cell growth. Biochem. J. 434: 83–92.
24. Jones, S., T. L. Wang, M. Shih Ie, T. L. Mao, K. Nakayama et al., 2010 Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228–231.
25. Kandoth, C., M. D. McLellan, F. Vandin, K. Ye, B. Niu et al., 2013 Mutational landscape and significance across 12 major cancer types. Nature 502: 333–339.
26. Kawabata, T., S. W. Luebben, S. Yamaguchi, I. Ilves, I. Matise et al., 2011 Stalled fork rescue via dormant replication origins in unchallenged S phase promotes proper chromosome segregation and tumor suppression. Mol. Cell 41: 543–553.
27. Kim, K. S., Y. B. Seu, S. H. Baek, M. J. Kim, K. J. Kim et al., 2007 Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol. Biol. Cell 18: 4543–4552.
28. Konermann, S., M. D. Brigham, A. E. Trevino, J. Joung, O. O. Abudayyeh et al., 2015 Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517: 583–588.
29. Krenning, L., F. M. Feringa, I. A. Shaltiel, J. van den Berg, and R. H. Medema, 2014 Transient activation of p53 in G2 phase is sufficient to induce senescence. Mol. Cell 55: 59–72.
30. Kuilman, T., C. Michaloglou, W. J. Mooi, and D. S. Peeper, 2010 The essence of senescence. Genes Dev. 24: 2463–2479.
31. Liang, H., L. W. Cheung, J. Li, Z. Ju, S. Yu et al., 2012 Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 22: 2120–2129.
32. Lobrich, M., and P. A. Jeggo, 2007 The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer 7: 861–869.
33. Maeda, D., and M. Shih Ie, 2013 Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv. Anat. Pathol. 20: 45–52.
34. Maeder, M. L., J. F. Angstman, M. E. Richardson, S. J. Linder, V. M. Cascio et al., 2013 Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 31: 1137–1142.
35. Mamo, A., L. Cavallone, S. Tuzmen, C. Chabot, C. Ferrario et al., 2012 An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31: 2090–2100.
36. Mao, Z., Z. Ke, V. Gorbunova, and A. Seluanov, 2012 Replicatively senescent cells are arrested in G1 and G2 phases. Aging (Albany, NY) 4: 431–435.
37. Pereira, J. J., T. Meyer, S. E. Docherty, H. H. Reid, J. Marshall et al., 2004 Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 64: 977–984.
38. Robinson, J. T., H. Thorvaldsdottir, W. Winckler, M. Guttman, E. S. Lander et al., 2011 Integrative genomics viewer. Nat. Biotechnol. 29: 24–26.
39. Romero, O. A., and M. Sanchez-Cespedes, 2014 The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene 33: 2681–2689.
40. Shen, J., Y. Peng, L. Wei, W. Zhang, L. Yang et al., 2015 ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 5: 752–767.
41. Shima, N., A. Alcaraz, I. Liachko, T. R. Buske, C. A. Andrews et al., 2007 A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat. Genet. 39: 93–98.
42. The Cancer Genome Atlas Network, 2012 Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
43. The Cancer Genome Atlas Research Network; C. Kandoth, N. Schultz, A. D. Cherniack, R. Akbani et al., 2013 Integrated genomic characterization of endometrial carcinoma. Nature 497: 67–73.
44. Trapnell, C., A. Roberts, L. Goff, G. Pertea, D. Kim et al., 2012 Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7: 562–578.
45. Waddell, N., M. Pajic, A. M. Patch, D. K. Chang, K. S. Kassahn et al., 2015 Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518: 495–501.
46. Wallace, M. D., A. D. Pfefferle, L. Shen, A. J. McNairn, E. G. Cerami et al., 2012 Comparative oncogenomics implicates the neuro-fibromin 1 gene (NF1) as a breast cancer driver. Genetics 192: 385–396.
47. Wallace, M. D., T. L. Southard, K. J. Schimenti, and J. C. Schimenti, 2014 Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress. Oncogene 33: 3688–3695.
48. Wang, K., J. Kan, S. T. Yuen, S. T. Shi, K. M. Chu et al., 2011 Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43: 1219–1223.
49. Wiegand, K. C., S. P. Shah, O. M. Al-Agha, Y. Zhao, K. Tse et al., 2010 ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363: 1532–1543.
50. Wu, R. C., T. L. Wang, and M. Shih Ie, 2014 The emerging roles of ARID1A in tumor suppression. Cancer Biol. Ther. 15: 655–664.
51. Zang, Z. J., I. Cutcutache, S. L. Poon, S. L. Zhang, J. R. McPherson et al., 2012 Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44: 570–574.
52. Zhang, Y., C. Yin, T. Zhang, F. Li, W. Yang et al., 2015 CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci. Rep. 5: 16277.
53. Zhao, J., C. Liu, and Z. Zhao, 2014 ARID1A: a potential prognostic factor for breast cancer. Tumour Biol. 35: 4813–4819.